Navigation Links
Breaking down Huntington's disease one protein at a time
Date:2/4/2008

BLOOMINGTON, Ind. -- Hoping to piece together the intricate series of interactions that lead to Huntington's disease, Indiana University Bloomington scientists have determined the shape and structure of a binding site that may prove useful in combating the neurodegenerative disease.

In the Feb. 1 issue of Journal of Molecular Biology, IU Bloomington biologists Joel Ybe and Qian Niu describe a region on the surface of HIP1 (Huntingtin-interacting protein 1) that could bind HIPPI (HIP1-protein interactor). The association of HIP1 and HIPPI is believed to lead to the degeneration of nerve cells.

"If we now think that this is the region where HIPPI binds, we could eventually design a drug that can come in and sit down between these two proteins, which would prevent the binding of HIPPI," said Ybe, who led the research.

Ybe and Niu's paper is the first to scrutinize a Huntington's disease-related protein's structure and function at the molecular level. Ybe and colleagues hope meticulous study of each Huntington's disease protein will suggest new avenues for wholesale prevention.

"The important thing for us is to come up with something that will potentially help people," said Ybe. "What is happening before the manifestation of the disease? Can we use this information to come up with drugs to diffuse that process?"

Huntington's disease is a hereditary disorder that causes large numbers of nerve cells to die. About 30,000 people in the U.S. are estimated to have the disease -- approximately one person in ten thousand. Symptoms include uncontrolled movements, dementia and depression, but these symptoms do not usually appear until the afflicted reach their 30s or 40s. Despite major strides forward in understanding the disease in recent years, there is currently no cure.

The disease begins when the huntingtin protein falls off HIP1. The vacancy allows another protein, HIPPI, to then bind to HIP1. The complex of
'/>"/>

Contact: Joel Ybe
jybe@bio.indiana.edu
812-856-4882
Indiana University
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. California Institute of Integral Studies Launches Groundbreaking Community Mental Health Program
2. Ground Breaking Program Improves Diabetes Patient Outcomes
3. Official Ground Breaking Ceremony for Cleveland Clinic Abu Dhabi
4. On The Go Ships 100TB Hardware Order for Ground-Breaking Cancer Imaging and Therapy Projects
5. VH1 Set to Continue Its Record-Breaking Pace Into 2008 with Brand New Premieres and Returning Series
6. Record-Breaking Financial Recovery Made in UnitedHealth Backdating Case
7. Breaking Studies at AARC Congress Show Masimo SET and Masimo Rainbow SET to be Accurate, Effective and Uniquely Beneficial in Detecting and Tracking Disease States
8. Breaking Down Barriers to End-of-Life Care for Children
9. Groundbreaking Study Reveals How Consumers Shop for Health Care
10. Video: BSP Pharma Inc. Announces Groundbreaking Findings from The Australian Centre for Complementary Medicine Education and Research Joint Health Clinical Study
11. Discovery Health Travels the World to Present the Groundbreaking Documentary - Diabetes: A Global Epidemic
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Breaking down Huntington's disease one protein at a time
Breaking down Huntington's disease one protein at a time
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8CBI Announces FDA Participation at Upcoming Forum on Clinical Trial Investigator Portals 14631 1CBI Announces FDA Participation at Upcoming Forum on Clinical Trial Investigator Portals 14631 2CBI Announces FDA Participation at Upcoming Forum on Clinical Trial Investigator Portals 14631 3Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 1Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 2Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 3Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 4Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 5Breast Health is a Year Round Priority 3A New Technology Identifies Risk of Breast Cancer in Younger Women 5779 1Breast Health is a Year Round Priority 3A New Technology Identifies Risk of Breast Cancer in Younger Women 5779 2Breast Health is a Year Round Priority 3A New Technology Identifies Risk of Breast Cancer in Younger Women 5779 3